Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More General business news Control Point Associates acquires Rouse-Sirine Associates to strengthen Mid-Atlantic surveying and S.U.E. expansion strategy Control Point Associates acquires Rouse-Sirine Associates to expand into Virginia and scale its geospatial services across the Mid-Atlantic. Read more. byVenkateshJanuary 24, 2026